12:00 AM
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BOW015: Phase I data

A double-blind, U.K. Phase I trial in 84 healthy male volunteers showed that a single 5 mg/kg infusion of BOW015 met the primary endpoint of bioequivalence to Remicade infliximab as measured by peak plasma concentration (Cmax) and area under the curve (AUC). Epirus...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >